NASDAQ: IONSIonis Pharmaceuticals Inc Stock
$43.78+0.93 (+2.17%)
Updated Aug 15, 2025
IONS Price
$43.78
Fair Value Price
N/A
Market Cap
$6.98B
52 Week Low
$23.95
52 Week High
$50.43
P/E
-24.88x
P/B
11.05x
P/S
6.66x
PEG
N/A
Dividend Yield
N/A
Revenue
$944.05M
Earnings
-$268.22M
Gross Margin
98.9%
Operating Margin
-19.4%
Profit Margin
-28.4%
Debt to Equity
3.73
Operating Cash Flow
-$231M
Beta
0.87
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
IONS Overview
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine IONS's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
IONS
Ranked#38 of 482
Ranked#38 of 482
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $13.15 | A | |
| $39.51 | A | |
| $12.27 | A |
Be the first to know about important IONS news, forecast changes, insider trades & much more!
IONS News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how IONS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
IONS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
IONS is poor value based on its book value relative to its share price (11.05x), compared to the US Biotechnology industry average (4.5x)
P/B vs Industry Valuation
IONS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more IONS due diligence checks available for Premium users.
Valuation
IONS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-24.88x
Industry
-120.52x
Market
35.99x
IONS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
11.05x
Industry
4.5x
IONS is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
IONS's financial health
Profit margin
Revenue
$452.0M
Net Income
$123.6M
Profit Margin
27.3%
IONS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
IONS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$3.0B
Liabilities
$2.4B
Debt to equity
3.73
IONS's short-term assets ($2.58B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IONS's short-term assets ($2.58B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IONS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
IONS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$151.3M
Investing
-$120.1M
Financing
$1.2M
IONS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
IONS vs Biotech Stocks
Ionis Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.